Join
Live feed
·
PRReleasevia Quantisnow
MeiraGTx Holdings plc logo

MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to Untreated Randomized Control

ByQuantisnow·Wall Street's wire, on your screen.
MGTX· MeiraGTx Holdings plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MGTX (MeiraGTx Holdings plc) and more on Quantisnow.